Coptis / Goldthread

What is Coptis?

The Chinese Pharmacopoeia sets a minimum of 5.5 percent berberine for weilian, the Coptis chinensis grade of Coptidis Rhizoma, and 3.0 percent for Phellodendron chinense bark, and the berberine capsule sold in a United States pharmacy is almost always made from neither plant. Coptis is the pharmacopoeial high-berberine herb. It is not the commercial source of berberine.

Coptis chinensis Franch. is a cultivated perennial of the buttercup family, Ranunculaceae, from southwest China, and the drug is the rhizome, a knotty chicken-claw cluster of yellow-orange segments, extremely bitter. The pharmacopoeia admits two others: Coptis deltoidea C.Y. Cheng et Hsiao, cultivated in Sichuan, and Coptis teeta Wall., endemic to the eastern Himalayas and Endangered on the IUCN Red List since 16 July 2014. Neither Coptis is CITES listed, while goldenseal is.

Common Names

• Coptis chinensis: huang lian, weilian (the dominant trade grade), Chinese goldthread. Coptis deltoidea: yalian. Coptis teeta: yunlian, or Mishmi tita in northeast India

• Coptis trifolia Salisb.: North American goldthread, savoyane, canker root. A different species with a different alkaloid profile

• Hydrastis canadensis L.: goldenseal, same family and different genus, also sold for its berberine, and the commonest thing a buyer confuses with goldthread. "Coptis spp." and "goldthread" also appear on real United States labels with no species name at all

Primary Active Compounds

Contents are for Coptis teeta rhizome, per a 2024 review by Chelleng and colleagues in Future Integrative Medicine, whose own berberine figures disagree: 78.99 to 84.85 milligrams per gram (Chen 2017), 72.93 to 90.96 (Li 2020), 8.0 to 8.5 percent by weight in a third source, 0.8 percent in a fourth.

• Berberine, the cation C20H18NO4 at 336.4 grams per mole (PubChem CID 2353), traded as the chloride salt C20H18ClNO4 at 371.8

• Then, per Chen 2017, coptisine 14.93 to 17.81 milligrams per gram, jatrorrhizine 6.07 to 7.76, palmatine 4.61 to 5.24, columbamine 1.58 to 1.73, epiberberine only 0.36 to 0.66, plus magnoflorine, an aporphine rather than a protoberberine, reported without a figure. Six alkaloids, in proportions differing sharply by species

Key Note

Every clinical result that gives berberine its reputation came from purified berberine hydrochloride measured out in milligrams, not from Coptis: Xu 2020, the best-documented, used 100 milligram tablets of greater than 98 percent purity. No single-herb Coptis product sold as goldthread states a berberine percentage, not the tinctures, not the 4:1 or 10:1 powders, not the whole-rhizome capsules, so a buyer cannot convert it into the units the trials used. The only United States labels printing a figure are multi-ingredient formulas using Coptis as a minor standardized extract, such as Patient One's Enflamen at 25 milligrams standardized for 5 percent berberine, which print a number because the Coptis is a garnish.

Coptis is a cultivated Chinese drug with a strict national monograph, a four-alkaloid assay, and almost no commercial relationship to the berberine aisle.

Primary Functions & Benefits

Berberine has replicated effects on glucose and lipids in type 2 diabetes, measured with purified compound at stated doses.

Glycemic control

Yin, Xing and Ye, Metabolism 2008, volume 57, pages 712 to 717, is the trial everything else anchors to, and it is smaller than its reputation. Study A randomized 36 adults with newly diagnosed type 2 diabetes to berberine hydrochloride or metformin, 18 to each arm, at 0.5 grams three times daily for three months; 15 of the berberine patients and 16 of the metformin patients finished. The berberine arm's hemoglobin A1c fell from 9.5 plus or minus 0.5 percent to 7.5 plus or minus 0.4, fasting glucose from 10.6 to 6.9 millimoles per liter, postprandial glucose from 19.8 to 11.1, and those are results in 15 people. Study B was not randomized and had no control group: it added berberine to existing sulfonylurea, metformin, acarbose or insulin treatment in 48 adults with poorly controlled disease, 43 of whom finished, with hemoglobin A1c falling from 8.1 to 7.3 percent and fasting insulin and HOMA-IR down 28.1 and 44.7 percent. The gastrointestinal figure usually quoted, 20 patients or 34.5 percent, is 20 of the 58 who completed berberine treatment across both studies. It is not 20 of 84, which counts the 18 who took metformin and never swallowed any berberine. Trial protocol numbers, not a dosing recommendation.

Lipids

Kong and colleagues, Nature Medicine 2004, volume 10, pages 1344 to 1351, gave berberine to 32 hypercholesterolemic patients for three months in an uncontrolled arm: cholesterol down 29 percent, triglycerides 35, LDL cholesterol 25. The pooled estimate is smaller. Ju 2018, 16 trials and 2,147 participants, found total cholesterol down 0.47 millimoles per liter (95 percent confidence interval minus 0.64 to minus 0.31), LDL cholesterol 0.38, triglycerides 0.28, HDL up 0.08. Across Guo 2021's 46 trials, fasting insulin fell 2.05, HOMA-IR 0.71 and body mass index 1.07, and Yan 2015 reported hepatic fat falling 52.7 against 36.4 percent on lifestyle alone (p equals 0.008, 184 patients).

Forms & Standardization

Two categories share a reputation and nothing else: purified berberine salts, where the dose is known and the trials live, and Coptis extracts, where it is not.

Berberine hydrochloride, the form the evidence belongs to

A 500 milligram capsule of the salt is not 500 milligrams of berberine, and anhydrous versus dihydrate changes the answer by about 40 milligrams. No United States label says which. Xu and colleagues, Cancer Prevention Research 2020, volume 13, pages 117 to 126, used 100 milligram tablets of greater than 98 percent pure berberine hydrochloride at 300 milligrams three times daily, isolated from Coptidis rhizome. That trial is the exception proving the rule: the Coptis was a feedstock, and what went in the capsule was a single compound with a certificate.

Two neighbors carry no outcome evidence: berberine sulfate, on 74 labels, and the phospholipid complex that raised area under the curve roughly tenfold on a molar basis in healthy volunteers in a manufacturer-written paper. The record does not transfer by salt-swapping.

Dihydroberberine

The reduced form, C20H19NO4 at 337.4 grams per mole, on 25 labels. One human trial: Moon 2022, Nutrients volume 14 article 124, a randomized crossover in five healthy men across four conditions, using dihydroberberine from its manufacturer NNB Nutrition. Peak plasma berberine ran 0.22 on placebo, 0.4 after 500 milligrams of berberine hydrochloride, 3.76 after 100 milligrams of dihydroberberine and 12.0 nanograms per milliliter after 200. So the 500 milligram capsule barely separated from placebo, while 200 milligrams of dihydroberberine, a strength actually sold, reached roughly thirty times its level. Glucose did not differ (p equals 0.97), nor insulin (0.24), and baseline berberine already differed between conditions (0.006). A pharmacokinetic signal, not a clinical one.

Coptis extracts, where standardization stops

The source plant in the berberine plus silymarin trials of section 16 is Berberis aristata titrated to 85 percent berberine, not Coptis. Coptis arrives in three shapes: dry extracts at a stated 4:1 or 10:1 with no alkaloid percentage; tinctures, whose real Dietary Supplement Label Database language runs from Herb Pharm's "dry herb / menstruum ratio: 1:5" through Hawaii Pharm's and Herbal Terra's 1:3 at 330 milligrams of dried plant material per milliliter, down to "Coptis Spp. Goldthread" at 1:1 naming no species; and patent formulas, where nothing is quantified.

A 10:1 ratio is a yield statement: ten kilograms of rhizome produced one of extract. At the 5.5 percent minimum with perfect recovery it would assay at 55 percent berberine and a 500 milligram capsule would hold 275. Recovery is never perfect, the ratio is sometimes computed on wet weight, and solvent selectivity decides which alkaloids come across, so the same capsule is equally consistent with 10 milligrams. The ratio constrains nothing, and that is the labeling, not a loophole in it.

What the two official standards require

The Chinese Pharmacopoeia monograph for Coptidis Rhizoma sets different bars for its three species. As monographed in the 2020 edition, weilian from Coptis chinensis must contain not less than 5.5 percent berberine, 0.80 percent epiberberine, 1.6 percent coptisine and 1.5 percent palmatine, each on the dried basis and all four quantified against the berberine hydrochloride reference standard; yalian from Coptis deltoidea not less than 4.5 percent berberine; yunlian from Coptis teeta not less than 7.0 percent. Prepared slices, which is what a sliced Coptis product actually is, are held to a different and looser shape of the same test: berberine not less than 5.0 percent, and the sum of epiberberine, coptisine and palmatine not less than 3.3 percent rather than three separate floors. A lot that passes as slices has not passed the crude-drug specification. The 2025 edition took effect on 1 October 2025, so the figures above are the 2020 ones, and a certificate of analysis that cites the Chinese Pharmacopoeia without naming an edition has not told you which numbers the lot was tested against. Ask which edition. Every one of those numbers is a floor: a rhizome assaying at 12 percent berberine passes the same monograph as one at 5.6 percent.

The United States Pharmacopeia monograph for Coptis Species Rhizome covers the same three species and is stricter: total quaternary protoberberine alkaloids not less than 9.0 and not more than 20 percent on the dried basis, summing columbamine, jatrorrhizine, epiberberine, coptisine, palmatine and berberine, with berberine itself 5.0 to 15. A ceiling as well as a floor, six alkaloids rather than four, and neither monograph reaches a United States supplement shelf.

Food Sources

There is no dietary source of berberine. No staple food contains it and no cuisine uses Coptis, because the rhizome is among the most bitter materials in Chinese medicine and is dosed in grams as a drug. A nutrient has an intake range evolution already tested on you; a pharmacologically active alkaloid with no dietary precedent does not. ANSES said so on 1 August 2019: berberine's pharmacological actions are confirmed at 400 milligrams a day and above, and its experts did not exclude lower doses acting the same way. That is a regulator calling a supplement ingredient a drug, with no floor below which it stops.

Who Should Take Coptis

Almost nobody should buy Coptis for the reason they think. If the goal is berberine's metabolic effect, buy berberine hydrochloride at a stated dose.

There is a conflict underneath this section that the marketing never mentions, and a reader deciding anything deserves both halves of it. Nearly all of berberine's human evidence sits in type 2 diabetes, so the people with the most reason to be interested are the people the trials enrolled. The French food safety agency ANSES, reviewing that same literature in its opinion of 1 August 2019, concluded that people with diabetes should abstain from berberine supplements, alongside pregnant and breastfeeding women and people with liver or heart disorders. ANSES did not find berberine ineffective. It found a pharmacologically active alkaloid, sold without a prescription, to a population already on titrated medication, with no safe intake established and adverse effects reported from 600 milligrams per day. Both readings follow from the evidence, and this issue is not going to resolve the tension in berberine's favor by leaving one of them out.

Candidates for berberine as a compound, with that conflict in view

• Adults with type 2 diabetes or prediabetes who are not pregnant, not breastfeeding, not on an interacting drug from section 7, and who treat it as an addition to a regimen their clinician knows about, understanding that ANSES would tell them not to take it at all. Guo and colleagues, Oxidative Medicine and Cellular Longevity 2021, article 2074610, assessed 46 trials and found hemoglobin A1c down 0.73 percentage points (95 percent confidence interval minus 0.97 to minus 0.51), but Guo pooled berberine used alone with berberine added to standard therapy and recommends it "especially as an adjunctive therapy." The larger pooling makes that distinction bite: Wang and colleagues, Frontiers in Pharmacology 2024, volume 15, article 1455534, across 50 studies and 4,150 participants, found a significant hemoglobin A1c reduction for berberine combined with hypoglycemic drugs (0.69 points) and no significant hemoglobin A1c effect for berberine alone, whose significant outcomes were fasting glucose, postprandial glucose and the lipids. Head to head, Dong and colleagues, Evidence-Based Complementary and Alternative Medicine 2012, article 591654, across 14 trials and 1,068 participants, found berberine did not beat metformin, glipizide or rosiglitazone, and Lan 2015 agreed. Choosing berberine over a prescription means choosing the less studied option, with the weaker standalone evidence on the marker that matters most

• Adults with elevated LDL cholesterol who cannot tolerate a statin, expecting the Ju 2018 figure of 0.38 millimoles per liter rather than the 25 percent from the uncontrolled 2004 arm

• Women with polycystic ovary syndrome and insulin resistance, where two randomized trials reported metabolic and reproductive gains (Wei 2012, An 2014)

• People using Coptis inside a traditional Chinese formula, where a practitioner is choosing a bitter cold herb for a pattern, not a berberine delivery system

• Anyone in those groups already on a glucose-lowering drug, who needs a baseline hemoglobin A1c and a monitoring plan first

Who Should AVOID or Use Caution

Contraindications

• Neonates, infants and jaundiced newborns. This is the most important sentence in this issue. Chan, Biology of the Neonate 1993, volume 63, pages 201 to 208, measured berberine's displacement of bilirubin from albumin in vitro at roughly tenfold the molar potency of phenylbutazone and a hundredfold that of papaverine, and in adult rats given 10 and 20 micrograms per gram intraperitoneally daily for a week, bilirubin protein binding fell while unbound and total bilirubin stayed elevated. Unbound bilirubin crosses into the brain, and kernicterus is the injury. Singapore removed berberine-containing preparations from sale in 1978, 15 years before Chan supplied that mechanism, on the suspected implication of berberine in worsening jaundice, hemolytic anemia and kernicterus in newborns with possible glucose-6-phosphate dehydrogenase deficiency. The human evidence is not uniform and the honest version says so: against those case reports, a study in more than a thousand infants found no difference in jaundice incidence between exposure to Chinese traditional medicine plants including berberine-bearing ones and no exposure (Ho, Goh and Zhang 2014), and Linn 2012 called the literature conflicting. The contraindication stands anyway, because displacement is a real competitive binding effect, the developmental toxicity data below point the same way, two national regulators have acted, and the cost of being wrong is an infant's brain. Lifting the 35 year prohibition effective 1 January 2013, Singapore's Health Sciences Authority stated on 21 November 2012 that berberine should still be avoided in infants, in glucose-6-phosphate dehydrogenase deficient individuals of all ages, and in pregnant and breastfeeding women

• Pregnancy and breastfeeding. The strongest reason here is not the bilirubin mechanism above, it is developmental toxicity measured directly. National Toxicology Program studies of berberine and of Hydrastis canadensis extracts found maternal toxicity (Jahnke and colleagues 2006) along with embryo-fetal toxicity and teratogenesis (National Toxicology Program 2002, 2003). Epidemiology following more than 14,500 births in Taiwan found a 3 percent prevalence of nervous system malformations that tracked first-trimester use of Rhizoma coptidis, taken by 1.5 percent of the pregnant women in the cohort, though the authors did not formally attribute the effect to berberine (Chuang and colleagues 2006). Berberine appears to cross the placenta and to pass into breast milk, and may increase uterine contractions. Chan's 1993 conclusion named pregnant women alongside jaundiced neonates, and ANSES in 2019 listed them among the populations that should not consume berberine

• Glucose-6-phosphate dehydrogenase deficiency at any age, per the Singapore position, and children and adolescents, per ANSES 2019, on absent data rather than a demonstrated injury

• People with diabetes, with liver disorders, or with heart disorders. ANSES named all three in 2019 among the populations that should abstain from berberine supplements. The first of those is the recommendation that sits most awkwardly against the trial literature, because the trials were run in exactly that group, and the agency reached it on the adverse-effect profile and the absence of an established safe intake rather than on any finding that berberine does not work. Section 6 states the conflict rather than hiding it

Use Caution

The drug interactions are not a footnote to the dosing section, they are why it needs a clinician. Guo and colleagues, European Journal of Clinical Pharmacology 2012, volume 68, pages 213 to 217, gave healthy men 300 milligrams three times daily for two weeks in a randomized crossover and probed five enzymes with named substrates: the urinary dextromethorphan to dextrorphan ratio over eight hours rose ninefold, the losartan to E-3174 ratio doubled, midazolam peak concentration rose 38 percent with area under the curve up 40 percent and oral clearance down 27 percent, while omeprazole and caffeine were unchanged. So CYP2D6, CYP2C9 and CYP3A4 fell and CYP2C19 and CYP1A2 came through clean. What follows:

• Cyclosporine. Wu and colleagues, European Journal of Clinical Pharmacology 2005, volume 61, pages 567 to 572, gave 0.2 grams of berberine three times daily for three months to 52 renal transplant recipients against 52 controls. Trough cyclosporine ran 29.3 percent higher and the concentration to dose ratio 27.8 percent higher. In a six patient substudy on cyclosporine 3 milligrams per kilogram twice daily, its area under the curve rose 34.5 percent, minimum concentration 88.3 percent, apparent clearance fell 40.4 percent and half-life lengthened 2.7 hours

• The CYP3A4 substrates in section 17, where a 40 percent rise in exposure moves a patient toward myopathy on a statin or oversedation on a benzodiazepine; the CYP2C9 ones, where losartan converts less to its active metabolite E-3174 and warfarin runs through the same enzyme; and the CYP2D6 ones, where a ninefold phenotypic shift is the size of a poor-metabolizer genotype

• Metformin, sulfonylureas, insulin and the SGLT2 and GLP-1 agents. Berberine lowers glucose, so stacking it under a drug titrated to your current glucose invites hypoglycemia. With metformin specifically the interaction is not only additive pharmacology: berberine inhibits the organic cation transporters OCT1 and OCT2 that handle metformin, and in rats given the two together intravenously metformin's early plasma concentration rose while its volume of distribution and systemic clearance fell (Kwon and colleagues 2015). An animal finding on a route nobody uses, but it means the two drugs interact at the transporter as well as at the glucose, and ANSES lists metformin among the identified pharmacokinetic interactions

The heart, which this issue previously left out

Berberine blocks the hERG potassium channel in vitro (Yu and colleagues 2017), the channel drug-induced QT prolongation runs through, and it can slow the heart: Cannillo and colleagues 2013 reported a clinical event in a patient taking berberine for cholesterol. A Coptis rhizome extract was cardiotoxic in a time and dose dependent way in the in vitro model the Food and Drug Administration uses for that screen, and so was palmatine, one of the four alkaloids the Chinese monograph requires (Zhang and colleagues 2018). That is mechanism plus a case report, not a measured human interaction. It is still why ANSES put people with heart disorders on its abstain list, why the World Health Organization advises against berberis, hydrastis and coptis in hypertension and prior cardiovascular disease, and why anyone on a QT-prolonging prescription should raise berberine with the prescriber.

If you substitute goldenseal, read this first

The likeliest real harm in this issue is not Coptis. It is a reader who cannot find goldthread, buys goldenseal for the same berberine, and stays on it for months. National Toxicology Program Technical Report 562 fed goldenseal root powder at up to 25,000 parts per million for 105 to 106 weeks and graded liver tumor findings by species and sex: clear evidence of carcinogenic activity in male and in female F344/N rats, some evidence in male B6C3F1 mice, no evidence in female mice. Those are lifetime feed concentrations, not human doses. The asymmetry is the point: goldenseal has a two-year bioassay that came back positive in both sexes of rat, Coptis has no bioassay at all, and EFSA cites rodent carcinogenicity among the signals behind its refusal to set a safe intake.

Critical Safety Point

Berberine inhibits three cytochrome P450 enzymes at 900 milligrams a day, the dose printed on ordinary bottles, with documented interactions against two narrow-index immunosuppressants. Do not add it to a prescription regimen without telling the prescriber, and do not take it around a newborn, a pregnancy or a jaundiced infant.

Recommended Dosages

Read section 7 first. Every figure below is a published trial protocol or traditional posology, reported so a label can be compared against it. None is a recommendation.

Berberine hydrochloride, the dose used in trials

500 milligrams three times daily, 1,500 per day, in Yin 2008 and Yan 2015. 300 three times daily, 900 per day, in Xu 2020 and Guo 2012. 1,000 per day in Di Pierro. Wang 2024 found the commonest dose across 50 studies to be 0.9 to 1.5 grams. All sit above the 600 milligrams at which ANSES says adverse effects begin.

Retail capsule strengths

A 500 milligram capsule labeled for two or three times daily. Three is 1,500 milligrams of salt, roughly 1,240 to 1,360 of berberine depending on the hydrate.

Dihydroberberine

No efficacy dose exists. Products carry 100 to 200 milligrams.

Coptis crude rhizome, traditional posology

1.5 to 10 grams of dried rhizome daily as a decoction, occasionally to 15, under a practitioner and not a capsule count.

Coptis crude rhizome inside a clinical trial

Kang 2024 gave Coptidis Rhizoma at 9, 27 or 45 grams daily inside Gegen Qinlian Decoction for 12 weeks. At the 5.5 percent floor that raw herb holds roughly 495, 1,485 and 2,475 milligrams of berberine, bracketing the purified trials on paper, but treat those as upper bounds rather than delivered doses, because a decoction does not extract everything. Supervised research, not a home protocol.

Coptis tinctures and extracts, what the dose actually delivers

Work it from the labels in section 4 rather than a generic tincture. Herb Pharm's 1:5 holds 200 milligrams of herb per milliliter, so a 1 milliliter dropperful carries about 11 milligrams of berberine at the 5.5 percent floor, and the label's own maximum of 40 drops four times daily, roughly 5.3 milliliters, comes to about 58 milligrams a day. Hawaii Pharm's 1:3 is stronger at 330 milligrams per milliliter, so a dropperful is about 18 milligrams and that label's maximum of 1 milliliter four times daily is about 73 milligrams a day. Against the 1,500 milligrams the glycemic trials used, a goldthread tincture taken to its own label maximum is short by a factor of roughly 20 to 30, and nothing on the bottle says so. Both of those are best-case numbers: they assume the floor is met and that every milligram of berberine in the herb ends up in the glass, and neither is true.

Duration

The glycemic and lipid trials ran 12 to 16 weeks, and Wang 2024 found cycles typically one to three months. The longest controlled trial here is Guarino's 52 weeks. There is no controlled safety data beyond one year, and EFSA's draft of 29 January 2026 could not set a safe intake for any assessed preparation.

Timing & Administration

Berberine hydrochloride is taken with food in essentially every published protocol, at breakfast, lunch and dinner, for two reasons. Tolerability: the dose-limiting problem is gastrointestinal and food blunts it. Mechanism: much of the effect is on postprandial glucose, so the drug has to be present when the meal is. Splitting matters because the plasma half-life is short relative to the dosing interval and absorption depends on a gut microbial reduction step.

Do not read the Moon 2022 schedule as a pattern to copy: its doses and 30 gram glucose test meal were built to put five fasted men on a two-hour curve, not to manage glycemia. Coptis tinctures are taken in water before meals in the bitter-tonic tradition, where the point is the taste, a logic the metabolic use does not borrow.

Timeline of Effects

One week to eight weeks

Glucose moves first: in study B of Yin 2008 berberine lowered fasting and postprandial glucose from week one onward. Gastrointestinal effects appear here too, usually transient, and lipids respond inside the three month protocols.

When to conclude it is not working

Hemoglobin A1c is fairly judged at 12 to 16 weeks, since the marker reflects about three months of glycemia; Yin 2008 read it at three months, Kang 2024 at 12 weeks, Yan 2015 at 16. If it has not moved by then at a trial-matching dose it is not arriving, and the largest pooling found no significant effect for berberine alone.

Benefits of Taking Coptis

Berberine's benefits are in section 3. Coptis has one dose-ranging trial, inside a multi-herb formula.

What Coptis itself has

Kang 2024 varied Coptidis Rhizoma from 9 to 45 grams daily inside Gegen Qinlian Decoction and got hemoglobin A1c falls of 0.26 (SD 0.79), 0.34 (0.71) and 0.75 (0.82) across the low, medium and high dose groups, significant by analysis of covariance, F equals 3.11, p equals 0.0492, while varying Puerariae Lobatae Radix from 24 to 120 grams in the companion study produced nothing, F equals 0.66, p equals 0.5206. Three caveats travel with it. The changes come from 106 completers of 122 randomized, and 7 of the 16 losses were in the 45 gram arm that carries the finding, against 5 at 27 grams and 4 at 9; for a bitter, gut-irritating herb that pattern flatters a dose-response. The most common adverse event, across all 122, was urinary protein-positive, followed by raised urinary leukocytes. And the authors themselves list no placebo arm, small groups and 12 weeks with no follow-up. It is still the best direct evidence that the Coptis in a Chinese formula does the glycemic work.

Potential Negatives & Side Effects

Gastrointestinal, the common one

Transient diarrhea, constipation, nausea, distension and cramping. In Yin 2008, 20 patients (34.5 percent of 58); in Ju 2018, adverse event rates did not differ from control (relative risk 0.64, 0.31 to 1.30). Dose splitting and food are the mitigations.

Hypoglycemia

Not a problem with berberine alone in the trials. A real problem underneath a titrated glucose-lowering drug, which is what a reader with type 2 diabetes is likeliest to do. ANSES named hypoglycemia and hypotension among its 2019 risks.

Liver

One episode of grade 3 transaminase elevation occurred among the 12 patients on berberine in Xu 2020, and resolved a month later. Yin 2008 reported no liver or kidney damage. ANSES names people with liver disorders among those who should abstain. EFSA's 2026 draft raises three hazard signals, and which plant each belongs to matters: herb-induced liver injury to Chelidonium majus, rodent carcinogenicity to goldenseal, genotoxicity to berberine itself. None is a frequency anyone can quote.

Deficiency Symptoms

What Coptis addresses

Nothing. There is no berberine requirement, no body pool, no transport protein, no deficiency syndrome and no test for status, unlike a genuine trace element.

Bottom line

These are diseases, not shortfalls. The question is whether a drug-like intervention belongs in your regimen, and whether the bottle holds what the trials used.

Toxicity Symptoms

At high intake

The first signal from crude Coptis is gastrointestinal: nausea, cramping and diarrhea, the traditional ceiling on the decoction and why the posology tops out near 10 to 15 grams. Purified berberine at 1,500 milligrams a day produced transient gastrointestinal effects in about a third of patients and no organ damage, and no acute poisoning syndrome is described.

ANSES puts a number between those poles that the supplement aisle ignores: reviewing the oral literature, it concluded that adverse effects attributable to berberine are observed from a daily dose of 600 milligrams in adults. Every protocol in section 8 runs above that.

The regulatory numbers run further below. Belgium caps isoquinoline alkaloids in supplements, expressed as berberine, at 10 milligrams a day, a figure ANSES examined and judged scientifically unjustified. ANSES derived an indicative toxicity value of 0.1 milligrams a day for a 60 kilogram person, one five-thousandth of a single 500 milligram capsule, while noting manufacturer-recommended European doses of 250 up to 1,200 milligrams. An indicative value is not a poisoning threshold, but the gap between 0.1 milligrams and 1,500 measures how unsettled this is.

Signs to reduce or stop

• Diarrhea or cramping that does not settle within a week or two

• Shakiness, sweating, confusion or palpitations, especially on metformin, a sulfonylurea or insulin

• Dark urine, right upper abdominal pain, unusual fatigue or yellowing of the eyes, warranting a stop and a liver panel

• Any new effect from a prescription after starting berberine: sedation on a benzodiazepine, muscle pain on a statin, a blood pressure drug that stopped working

General note

The one toxicity that is not dose-dependent in the usual sense is the neonatal one. Displacement of bilirubin from albumin is a competitive binding effect, shown in vitro and in rats rather than measured in human infants, so no casual amount can be called safe in a jaundiced newborn even though the human outcome data are mixed. That is why a national regulator removed the molecule from sale for 35 years rather than capping it.

How Coptis Alkaloids Work

Berberine is a quaternary ammonium cation, permanently charged at every physiological pH: water-friendly, membrane-hostile, a magnet for efflux pumps. Almost none of an oral dose reaches the blood.

The absorption problem, quantified

Chen 2011, AAPS PharmSciTech volume 12 pages 705 to 711, measured absolute oral bioavailability in rats at 0.68 percent. That is a rat figure, often quoted as though human. Nobody has dosed berberine intravenously in humans, so the honest human data are concentrations: plasma 3.5 nanomoles per liter after three months at 900 milligrams a day (Xu 2020), serum 6.99 nanograms per milliliter after 16 weeks at 1,500 (Yan 2015). Taking 1.5 grams to reach single-digit nanograms per milliliter is a compound that mostly never leaves the gut.

The microbial activation step

Feng 2015, Scientific Reports volume 5 article 12155, resolved how any of it gets in: gut bacterial nitroreductases reduce berberine to dihydroberberine, absorbed about five times as readily, which oxidizes back inside intestinal tissue. Antibiotics in mice cut the conversion, the blood berberine and the glucose and lipid effects together. The microbiome is part of the dosing apparatus.

What it does once inside

Three routes, all Tier 3: AMP-activated protein kinase activation downstream of mitochondrial complex I inhibition; raised liver LDL receptor expression by messenger RNA stabilization, which Kong 2004 showed is not the statin route; and action in the lumen on the gut flora. The other five alkaloids share the charge problem and have no trial. Absence of a trial is not absence of a signal: palmatine was cardiotoxic in the in vitro model the Food and Drug Administration uses for that screen, as was a whole Coptis rhizome extract (Zhang 2018). A Coptis extract is not a weak berberine capsule but a six-alkaloid mixture in unstated proportions, one component studied in people and another flagged.

Synergistic Supplements

Silymarin, the only pairing with human outcome data

Di Pierro 2013 compared a fixed combination against Berberis aristata alone in 69 patients with type 2 diabetes, at 1,000 milligrams per day of berberine plus 210 of silymarin, and hemoglobin A1c fell further on the combination; the proposed reason is that silymarin inhibits P-glycoprotein. The authors call it preliminary with no randomization or blinding, so the controlled evidence is Guarino 2017: the same pairing for 52 weeks, double-blind and placebo-controlled, in 136 obese patients, in a since-delisted journal.

The pairing that is a hazard rather than a synergy

In Lan 2015, berberine plus oral hypoglycemics gave better glycemic control than the hypoglycemics alone. Read as a benefit it sells capsules. Read correctly it is a dose adjustment belonging to whoever wrote your prescription.

Interactions & What NOT to Take

Berberine's human cytochrome P450 profile is in section 7.

Do not combine without a prescriber's involvement

• Cyclosporine, the documented one: trough 29.3 percent higher across 52 patients against 52 controls, area under the curve 34.5 percent higher and minimum concentration 88.3 percent higher in the substudy (Wu 2005)

• Tacrolimus, documented and not an extrapolation. Hou, Han and Fu, European Journal of Clinical Pharmacology 2013, volume 69, pages 1861 to 1862, reported an adolescent on tacrolimus for idiopathic nephrotic syndrome whose circulating tacrolimus rose after starting 600 milligrams of berberine a day, with the drug's renal toxicity worsening. One patient, but a measured interaction with harm attached, and ANSES lists tacrolimus among the identified pharmacokinetic interactions. Sirolimus is the extrapolation, on the same CYP3A4 and P-glycoprotein logic

• A QT-prolonging prescription of any kind, on hERG blockade and the bradycardia case in section 7. Mechanism plus one report, so a question for the prescriber rather than an assumed problem

• Simvastatin, atorvastatin and lovastatin; midazolam, triazolam and alprazolam

• Losartan, where inhibiting CYP2C9 reduces formation of the active metabolite, and warfarin

• Metoprolol, carvedilol, propafenone and flecainide, plus fluoxetine, paroxetine, venlafaxine, amitriptyline, risperidone, aripiprazole and haloperidol

• Codeine and tramadol, which need CYP2D6 to become active, so inhibition can mean less pain relief, and tamoxifen, which needs CYP2D6 to become endoxifen

• Digoxin, on P-glycoprotein. Berberine is both substrate and inhibitor and raised digoxin bioavailability in rodents, an animal finding and a reason for caution rather than a measured human interaction

• Metformin, glipizide, glimepiride, insulin, and the SGLT2 and GLP-1 agents, for additive glucose lowering

Do not take at all

• In pregnancy or while breastfeeding, and anywhere in a newborn's dosing, including any Chinese patent formula given to an infant

• With known glucose-6-phosphate dehydrogenase deficiency, per the Singapore Health Sciences Authority position of 21 November 2012

Other practical conflicts

• Broad-spectrum antibiotics, which remove the bacteria that activate the dose

• Other berberine sources stacked unknowingly. A berberine capsule, a goldenseal capsule and an Oregon grape tincture are three doses of one alkaloid, and only one puts a number on it

• Surgery. Stop at least a week before a planned procedure, for the glucose effect and the CYP3A4 inhibition of agents including midazolam

Quality, Testing & Adulteration

Documented failures

• Berberine products. NOW Foods, December 2023, tested 33 bought on Amazon and Walmart.com by HPLC with ultraviolet detection, verified at Alkemist Labs: no product but NOW's own reached label claim, 18 held under 40 percent and seven held 1 percent or less. NOW sells berberine, so this is a competitor's survey, not a neutral audit. SuppCo, 22 October 2025, sent 13 to an ISO 17025 laboratory: seven missed half their claim, both gummies held none

• Goldenseal products, which fail worse. ConsumerLab, 12 December 2017: 67 percent of those it selected fell short of expected berberine against the United States Pharmacopeia's Goldenseal monograph, which requires not less than 2.5 percent berberine and 2.0 percent hydrastine on the dried basis, and one carrying multiple quality seals had none detectable. On 14 September 2023 it found two contaminated with lead

Species substitution, and the test that catches it

A second monograph does the detecting. The United States Pharmacopeia's Powdered Goldenseal Extract monograph requires not less than 5 percent hydrastine, not less than 10 percent for berberine and hydrastine summed on the dried basis, and a berberine to palmatine peak area ratio above 50 to 1. It sets no individual minimum for berberine, which is why the 67 percent figure above is measured against the crude Goldenseal monograph instead; using the wrong one is the easiest mistake in this aisle. Goldenseal carries almost no palmatine while Coptis, Phellodendron and Berberis carry a great deal, so cheapen goldenseal with an Asian berberine plant and the palmatine peak rises and the ratio collapses. Hydrastine, present only in Hydrastis, is the positive marker.

Within the genus the marker is palmatine, not coptisine. Kamath, Skeels and Pai, Chinese Medicine 2009, volume 4, article 17, found palmatine unique to Coptis chinensis and hydrastine unique to Hydrastis, while coptisine turned up in all three. It also complicates this issue's framing: Hydrastis held the most berberine, so carrying the pharmacopoeial floor is not being the richest source.

Synthetic berberine in the supply chain

Perini 2026, Journal of Food Composition and Analysis volume 151 article 108989, showed that stable isotope analysis can distinguish plant-derived berberine from synthetic in Berberis aristata material. It also counts how many commercial samples sold as natural carried the synthetic signature, a figure deliberately not quoted here because the full text could not be reached to check it. Until this work "natural" had no routine test behind it, and the test needs a laboratory no buyer has.

What a certificate should let you check

A USP Verified mark audits manufacturing and identity and NSF covers contaminants and label accuracy, but neither says which plant the berberine came from, and most products carry no mark. Check:

• Whether the label names a species and a plant part. "Coptis spp." and "goldthread" do not

• Whether a Coptis extract states a berberine or total alkaloid percentage. Only 4:1 or 10:1 is a yield, not a dose

• Whether a berberine product states the salt and the hydrate

• Whether the certificate reports the six alkaloids by HPLC with the chromatogram, rather than a total alkaloid number by titration that cannot tell berberine from palmatine

Conservation

Coptis chinensis is cultivated, so wild collection is not the pressure point. The relatives are. Hydrastis canadensis is in CITES Appendix II, on a United States proposal stating that of the 27 states in its range, "in 17 of them it is considered critically imperiled, imperiled, or uncommon." Coptis teeta is Endangered but not CITES listed. The ethical ranking reverses the price ranking: the cultivated Chinese species is the sustainable one, and the American substitute carries the trade controls.

Special Considerations

Newborn and infant exposure through a formula

The risk route is not a capsule but a Chinese patent medicine or decoction containing huang lian given to an infant, as the Singapore concern arose. If an infant in your household is jaundiced, nothing containing Coptis, Phellodendron, goldenseal or berberine belongs in the house.

Glucose-6-phosphate dehydrogenase deficiency

The Singapore position excludes deficient individuals at any age, and ANSES names them too. No controlled trial has tested berberine in this group, and the study usually cited does not supply one: Linn 2012 followed 20 adults with chronic cytopenic blood disorders, thalassemia intermedia among them, on Coptidis Rhizoma for 1,055 patient-days and Phellodendron bark for 1,252, and the paper does not describe that cohort as enzyme-deficient. The authors found no organ toxicity, saw transient bilirubin rises in three thalassemia intermedia patients without worsening anemia, and called the literature conflicting. Read it as what it is, not reassurance about a deficiency it did not study.

Research Status & Evidence Quality

Evidence tiers

• Tier 1, replicated randomized trials: berberine on glycemia and lipids in type 2 diabetes, firmest as an add-on

• Tier 2, one or two adequate trials: fatty liver, polycystic ovary syndrome, Coptidis Rhizoma in a formula

• Tier 3, mechanism without translation: AMPK activation, LDL receptor messenger RNA stabilization, microbial conversion to dihydroberberine. The cytochrome P450 work is human, the rest cell and animal

• Tier 4, single small studies: dihydroberberine pharmacokinetics, phospholipid-complexed berberine, ulcerative colitis, acute bronchitis, hERG and cardiotoxicity

• Tier 5, no human evidence: Coptis extract at a stated ratio for any metabolic indication, the five non-berberine alkaloids alone, berberine sulfate

Research Limitations

• Quality, in the reviewers' own words. Lan 2015 called its trials' overall quality limited, Dong 2012 called methodological quality generally low, and Ju 2018 judged its trials at high risk of selection, performance, detection, attrition and confounding bias. These are the people making the case for berberine, and most of the trials are Chinese

• Completer analysis. Kang 2024's hemoglobin A1c changes come from 106 completers of 122 randomized, with the heaviest dropout in the arm carrying the finding, and Yin 2008's headline falls come from 15 and 43 completers

• No hard outcome data. No trial has tested whether berberine reduces cardiovascular events, kidney disease progression or death, and no controlled safety data run past 52 weeks

• The null results are real. Berberine did not beat metformin or the other oral hypoglycemics, dihydroberberine raised plasma berberine without changing glucose or insulin, and varying the Puerariae dose did nothing

• As of October 2026, searches for a randomized trial of a standardized Coptis extract at a 4:1 or 10:1 ratio for a metabolic indication returned none

Summary & Key Takeaways

Bottom Line

Coptis chinensis is the pharmacopoeial high-berberine herb, at not less than 5.5 percent berberine for weilian and 5.0 to 15 percent under the stricter United States Pharmacopeia monograph. Berberine is one of the better-evidenced supplement ingredients, pooled at 0.73 hemoglobin A1c points across 46 trials, though that pooling mixes monotherapy with add-on use and the largest review found no significant effect for berberine alone. Those facts barely connect to Coptis: the trials used purified berberine hydrochloride at 900 to 1,500 milligrams a day, and the shelf product comes from Berberis aristata, on 560 NIH labels against 69 for Coptis chinensis. A goldthread tincture at its label maximum delivers 60 to 70 milligrams a day at best. If you want the evidence, the compound carries it, and the first conversation is with whoever manages your medication.

Key Safety Points

• Never give anything containing berberine, Coptis, Phellodendron or goldenseal to a newborn or a jaundiced infant. The mechanism is bilirubin displacement and the injury is kernicterus; section 7 states both sides of a mixed human record. Treat it as absolute anyway

• Avoid in pregnancy and breastfeeding, where developmental toxicity is the stronger argument, and in glucose-6-phosphate dehydrogenase deficiency at any age

• ANSES also tells people with diabetes, liver disorders or heart disorders to abstain, which covers most of this issue's likely readers

• Tell your prescriber first. At 900 milligrams a day berberine cut CYP2D6 ninefold, halved CYP2C9, raised midazolam exposure 40 percent and cyclosporine troughs 29.3 percent, and raised tacrolimus with renal toxicity in a reported case

• Expect additive glucose lowering on metformin, a sulfonylurea or insulin, and monitor rather than treating it as a bonus

• Do not stack a berberine capsule, a goldenseal capsule and an Oregon grape tincture. Three doses of one alkaloid, one number

Special Note

A buyer with prediabetes holding two bottles, one labeled goldthread extract 10:1 and one berberine HCl 500 milligrams, is looking at the plant with the research tradition and the molecule with the research. The 10:1 guarantees nothing: at the pharmacopoeial floor with perfect recovery it would be 55 percent berberine, and it is equally consistent with 2 percent. The berberine bottle states a number comparable with Yin 2008, though in the 2023 and 2025 surveys it had a better than even chance of holding under half of it, which a certificate of analysis by HPLC would catch. The larger question is not solvable by label reading, and it comes first: this reader has a diagnosis, probably a prescription, and is considering a compound that inhibits three cytochrome P450 enzymes, lowers glucose additively, and that the French regulator says people with diabetes should not take as a supplement. That belongs in front of a clinician before either bottle is opened.

Researched and drafted with AI assistance. Every claim verified against primary sources and human-reviewed before publication. Last reviewed: [DATE]. Corrections: reply to any issue.

This issue is educational and is not medical advice. If you take prescription medication, have diagnosed diabetes or prediabetes, are pregnant or breastfeeding, have glucose-6-phosphate dehydrogenase deficiency, or care for a newborn, talk to a clinician before changing anything.